Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Jessica Whitten Biography and Net Worth

CAO of bluebird bio

Audit Professional with global audit background in insurance, financial services, healthcare, technology and manufacturing industries. 20+ years experience in business process evaluation and design, enterprise risk management, system implementations and financial reporting. Proven ability to build and lead teams during periods of change and drive organizational efficiencies through effective planning, coaching, and administration.

How do I contact Jessica Whitten?: The corporate mailing address for Ms. Whitten and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at [email protected]. Learn More on Jessica Whitten's contact information.
Has Jessica Whitten been buying or selling shares of bluebird bio?: Jessica Whitten has not been actively trading shares of bluebird bio in the last ninety days. Most recently, Jessica Whitten sold 130 shares of the business's stock in a transaction on Monday, January 10th. The shares were sold at an average price of $9.40, for a transaction totalling $1,222.00. Learn More on Jessica Whitten's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 34,859 shares worth more than $107,838.66. The most recent insider tranaction occured on February, 5th when insider Thomas J Klima sold 2,714 shares worth more than $2,442.60. Insiders at bluebird bio own 2.1% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 2/5/2024.

Jessica Whitten Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/10/2022	Sell	130	$9.40	$1,222.00
1/5/2022	Sell	2,984	$10.44	$31,152.96

Jessica Whitten Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $0.91

$0.88

$0.93

50 Day Range

MA: $1.26

$0.91

$1.75

2 Week Range

Now: $0.91

$0.88

$5.53

Volume

5,710,078 shs

Average Volume

8,794,342 shs

Market Capitalization

$99.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74